Icecure Medical Rides FDA, ASBRS Wins to Growth

Icecure Medical Ltd. ((ICCM)) has held its Q4 earnings call. Read on for the main highlights of the call.

Icecure Medical’s latest earnings call struck an optimistic tone, with management highlighting strong regulatory wins, a key professional endorsement, and record 2025 revenue of $3.4 million. While executives acknowledged execution and reimbursement timing risks, they emphasized growing commercial traction, expanding clinical evidence, and a robust pipeline that together suggest the business is entering a meaningful growth phase.

Record Revenue and Quarterly Sales

Icecure reported record fourth‑quarter sales of about $1.3 million and full‑year revenue of $3.4 million from sales for 2025. Management framed these results as an early proof point that its breast‑cancer cryoablation platform is starting to convert clinical interest into paying customers, even before full reimbursement and global approvals are in place.

U.S. FDA Clearance for ProSense

The standout catalyst was U.S. FDA marketing authorization in October 2025 for ProSense to treat low‑risk breast cancer in women 70 and older and patients not suitable for surgery. This makes ProSense the first and only FDA‑cleared device for breast‑cancer cryoablation in the U.S., giving Icecure a differentiated, protected position in a niche that could expand as data accumulates.

Major Medical Society Endorsement

Adding to the regulatory win, the American Society of Breast Surgeons’ 2026 guidance now recommends cryoablation as an option for selected biologically low‑risk early‑stage breast cancer. Management views this as a powerful validation that should both ease surgeon adoption and support eventual reimbursement upgrades as payers align with society guidelines.

Growing U.S. Commercial Momentum and Pipeline

Executives highlighted a growing pipeline of U.S. customers moving from leads to signed contracts, deliveries, and installations, citing examples such as Fuel Imaging and Thomas Hospital. They expect system sales and installations to pick up from the second quarter of 2026 and continue rising through the year as more centers gain experience and word of mouth builds.

Post‑Marketing Study Planning and Enrollment Targets

To satisfy FDA requirements, Icecure must run a 30‑site hybrid post‑marketing study, and management said most of these sites have already been identified. Onboarding is planned over the next three to six months, with all 30 sites targeted to be open by the end of next year and roughly 20% of patients enrolled by this time next year.

Existing Reimbursement and Potential Upside

Today, procedures are covered by an existing CPT facility payment of about $4,000, which provides a baseline economic framework for hospitals. Upside could come from a transitional pass‑through payment that might add up to $900 per procedure by early 2027 and a CPT1 physician reimbursement filing in the second quarter of 2026 that, if successful, could become effective in early 2028.

Global Regulatory and Clinical Expansion

Icecure is also pushing beyond the U.S. with a Class III amended application to Health Canada for treating early‑stage low‑risk invasive breast cancer in patients aged 60 and above. In Japan, the company and partner Terumo completed a PMDA consultation with positive feedback, and management noted rising international demand since the U.S. clearance, although final approvals remain pending.

Strong Scientific and Awareness Momentum

The company reported a record year for scientific visibility in 2025, with 60 principal investigators presenting at 10 conferences and a growing list of peer‑reviewed publications. Independent studies such as SIXT in Brazil and PRECISE in Italy, coupled with active social media promotion, are expected to support physician confidence and drive patient referrals.

Commercial Team Expansion

To keep pace with interest, Icecure plans to roughly triple its U.S. commercial team by the end of 2026, implying about three times growth in sales headcount. Management believes this investment is critical to converting growing leads into contracted sites and to supporting training, utilization, and ongoing physician engagement as installations ramp.

Reimbursement and Execution Risks

Despite positive trends, management acknowledged that broader reimbursement is still a work in progress, with key decisions on pass‑through payments and CPT1 timelines not expected until 2027 and 2028. They also flagged execution risks around post‑marketing study site conversion, long sales cycles of up to nine months, regional regulatory timing, and limited disclosed detail on production ramp that could all affect the pace of revenue growth.

Forward‑Looking Guidance and Outlook

Looking ahead, Icecure expects commercial momentum to accelerate off the record fourth quarter, with system sales and installations increasing from the second quarter of 2026 and continuing to grow through the year. Management’s plan hinges on opening all 30 post‑marketing sites by the end of 2027, tripling the U.S. commercial team, and capturing reimbursement enhancements and international approvals that together could materially expand procedure volumes.

Icecure’s earnings call painted a picture of a company transitioning from clinical development to commercial scale, anchored by unique FDA clearance and society backing for ProSense. While reimbursement and execution risks remain, record revenue, a deepening clinical and regulatory moat, and a growing commercial footprint suggest the stock will increasingly trade on its ability to convert these catalysts into sustained revenue growth.